Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3... by Rummel, Mathias J, Prof Dr, Niederle, Norbert, Prof, Maschmeyer, Georg, Prof, Banat, G Andre, MD, von Grünhagen, Ulrich, MD, Losem, Christoph, MD, Kofahl-Krause, Dorothea, MD, Heil, Gerhard, Prof, Welslau, Manfred, MD, Balser, Christina, MD, Kaiser, Ulrich, Prof, Weidmann, Eckhart, Prof, Dürk, Heinz, MD, PhD, Ballo, Harald, MD, Stauch, Martina, MD, Roller, Fritz, MD, Barth, Juergen, Pharm, Hoelzer, Dieter, Prof, Hinke, Axel, PhD, Brugger, Wolfram, Prof

Get full text

Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority,... by Hegewisch-Becker, Susanna, Prof, Graeven, Ullrich, MD, Lerchenmüller, Christian A, MD, Killing, Birgitta, MD, Depenbusch, Reinhard, MD, Steffens, Claus-Christoph, MD, Al-Batran, Salah-Eddin, Prof, Lange, Thoralf, Prof, Dietrich, Georg, MD, Stoehlmacher, Jan, Prof, Tannapfel, Andrea, Prof, Reinacher-Schick, Anke, Prof, Quidde, Julia, MD, Trarbach, Tanja, MD, Hinke, Axel, PhD, Schmoll, Hans-Joachim, Prof, Arnold, Dirk, Prof

Get full text

Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority... by Rummel, Mathias, Prof, Kaiser, Ulrich, Prof, Balser, Christina, MD, Stauch, Martina, MD, Brugger, Wolfram, Prof, Welslau, Manfred, MD, Niederle, Norbert, Prof, Losem, Christoph, MD, Boeck, Hans-Peter, MD, Weidmann, Eckhart, Prof, von Gruenhagen, Ulrich, MD, Mueller, Lothar, MD, Sandherr, Michael, MD, Hahn, Lars, MD, Vereshchagina, Julia, MD, Kauff, Frank, PhD, Blau, Wolfgang, MD, Hinke, Axel, PhD, Barth, Juergen, Pharmacist

Get full text